Driving Innovation in Vaccine Research and Development
At BioNet, our Research and Development (R&D) efforts are at the forefront of vaccine innovation, combining cutting-edge science with a mission to address urgent public health challenges. Our R&D focuses on creating next-generation vaccines using advanced platforms, including recombinant, DNA, and mRNA technologies.
Revolutionizing Vaccine Platforms
Targeting
Global Health
Threats
BioNet’s development pipeline focuses on combating respiratory diseases, vector-borne illnesses, and zoonotic infections, with a strong emphasis on re-emerging and pandemic threats. By addressing these critical areas, we aim to deliver innovative vaccines that improve global health outcomes.
Key Achievements and Milestones
Completion of 15+ successful clinical trials validating the safety and efficacy of our Pertussis vaccines.
Rapid development of mRNA vaccine candidates, including pancoronavirus candidate, using state-of-the-art platforms.
Expansion of our pipeline to address
emerging infectious diseases and unmet
medical needs.
Proprietary mRNA Platform
Our unique and flexible mRNA plug-and-play platform is highly adaptable for pandemic preparedness. We have developed multiple candidates against potential threats, leveraging the platform’s ability to quickly respond to emerging pathogens including:
– Avian influenza
– Pandemic influenza
– Combination Flu-CoV-RSV
Our platform enables development of a wide range of vaccines candidates:
– Research lot in 10 days
– GMP lot in 100 days
Clinically Proven Solution
Through the establishment of global and strategic R&D consortia, our mRNA process development demonstrates effectiveness, safety and adaptability to emerging variants. These collaborative efforts ensure that we stay at the forefront of innovation, continuously improving our methodologies to meet the evolving challenges of public health, and enabling fast trajectories to clinical trials:
Monovalent SARS-CoV-2 (Wuhan):
– Phase 1 Primary immunization in Thailand
– Phase 2 Booster trial in Australia
Bivalent SARS-CoV-2 (Wuhan/Omicron):
– Phase 2 Booster Trial in Australia
Committed to Transforming Global Health
At BioNet, we believe that innovation is the key to a healthier, safer world. Our R&D teams work tirelessly to bring groundbreaking vaccine solutions to market, ensuring access to life-saving immunizations for all.